- Home
- CNF vs MIST Comparison
CNF vs MIST Comparison
Compare CNF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | MIST |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | China | Canada |
| Employees | N/A | 38 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6M | 146.9M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CNF | MIST |
|---|---|---|
| Price | $2.21 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 5.5K | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $252.34 | $2,915.14 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.04 | $1.00 |
| 52 Week High | $6.49 | $3.06 |
Technical Indicators
Market Signals| Indicator | CNF | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 55.43 |
| Support Level | $2.07 | $1.20 |
| Resistance Level | $2.35 | $1.42 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 28.09 | 77.08 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, the group generates all of its revenues in the PRC.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.